Latest News and Press Releases
Want to stay updated on the latest news?
-
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
-
Gyre's Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Liver Fibrosis Trial
-
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
-
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
-
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
-
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
-
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
-
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension